Cite

    Alexander Faje et al.. “Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.” European journal of endocrinology, vol. 181, no. 3, 2019, pp. 211–219. http://access.bl.uk/ark:/81055/vdc_100091297917.0x000044